Kingsley Biotechnology (01548): Legend announced that it will be exhibited at the American Society of Hematology Annual Meeting

Zhitongcaijing · 1d ago

Zhitong Finance App News, Kingsley Biotech (01548) issued an announcement. Legend Biotechnology Co., Ltd. (“Legend”, an associated company whose shares are listed on the US NASDAQ Global Select Market in the form of American Depositary Shares) will submit Form 6-K to the US Securities and Exchange Commission on November 4, 2026 (New York time) (after the Hong Kong trading session on November 4, 2026). It was also announced that it will present two oral reports, two poster presentations, and an electronic publication on the research results of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in the treatment of multiple myeloma at the 68th Annual Meeting of the American Society of Hematology to be held in New Orleans, Louisiana, USA from December 12 to 15, 2026. In addition to the CARYVKTI data, LEGEND will also present in poster form its allogeneic gamma-delta CAR-T therapy LUCAR G39D targeting CD20/CD19, which is used to treat recurrent or refractory B-cell non-Hodgkin lymphoma, and the first in vivo CD19/CD20 dual-target CAR-T therapy LB2501, which is currently being evaluated for treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.